These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 12352398

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.
    Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN.
    Urology; 2002 Feb; 59(2):227-31. PubMed ID: 11834391
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
    Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W.
    J Urol; 2004 Oct; 172(4 Pt 1):1271-5. PubMed ID: 15371822
    [Abstract] [Full Text] [Related]

  • 26. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma.
    Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Segura JW, Zincke H, Elliott DS, Blute ML.
    J Urol; 2007 May; 177(5):1721-6. PubMed ID: 17437796
    [Abstract] [Full Text] [Related]

  • 27. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ, van der MEIJDEN AP, Lamm DL.
    J Urol; 2002 Nov; 168(5):1964-70. PubMed ID: 12394686
    [Abstract] [Full Text] [Related]

  • 28. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
    Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.
    J Endourol; 2017 Sep; 31(9):946-953. PubMed ID: 28731777
    [Abstract] [Full Text] [Related]

  • 29. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study.
    Jamil ML, Deebajah M, Sood A, Alanee S.
    BMJ Open; 2019 Dec 03; 9(12):e027066. PubMed ID: 31796469
    [Abstract] [Full Text] [Related]

  • 30. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.
    Miller EB, Eure GR, Schellhammer PF.
    Urology; 1993 Jul 03; 42(1):26-30. PubMed ID: 8328123
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study.
    Colin P, Ouzzane A, Pignot G, Ravier E, Crouzet S, Ariane MM, Audouin M, Neuzillet Y, Albouy B, Hurel S, Saint F, Guillotreau J, Guy L, Bigot P, De La Taille A, Arroua F, Marchand C, Matte A, Fais PO, Rouprêt M, French Collaborative National Database on U.U.T.-U.C.
    BJU Int; 2012 Oct 03; 110(8):1134-41. PubMed ID: 22394612
    [Abstract] [Full Text] [Related]

  • 33. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS.
    Urology; 2006 Apr 03; 67(4):737-41. PubMed ID: 16618564
    [Abstract] [Full Text] [Related]

  • 34. Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?
    Giannarini G, Kessler TM, Birkhäuser FD, Thalmann GN, Studer UE.
    Eur Urol; 2011 Nov 03; 60(5):955-60. PubMed ID: 21807456
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
    Okubo K, Ishitoya S, Maeda H, Suzuki Y, Arai Y.
    Nihon Hinyokika Gakkai Zasshi; 1997 Mar 03; 88(3):386-90. PubMed ID: 9125861
    [Abstract] [Full Text] [Related]

  • 37. Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ.
    Studer UE, Casanova G, Kraft R, Zingg EJ.
    J Urol; 1989 Oct 03; 142(4):975-7. PubMed ID: 2795755
    [Abstract] [Full Text] [Related]

  • 38. Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
    Ryoo H, Kim J, Kim T, Kang M, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Sung HH.
    Cancer Res Treat; 2021 Jul 03; 53(3):795-802. PubMed ID: 33421984
    [Abstract] [Full Text] [Related]

  • 39. Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients.
    Katims AB, Tam AW, Rosen DC, Zampini AM, Atallah W, Mehrazin R, Gupta M.
    Urol Oncol; 2021 Apr 03; 39(4):234.e9-234.e13. PubMed ID: 32958446
    [Abstract] [Full Text] [Related]

  • 40. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival?
    Maulard-Durdux C, Dufour B, Hennequin C, Chrétien Y, Vignes B, Droz D, Delanian S, Housset M.
    J Urol; 1996 Jan 03; 155(1):115-7. PubMed ID: 7490805
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.